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The	pharmaceutical	industry	is	at	risk	from	Brexit
The	pharmaceutical	industry	is	at	risk	from	Brexit.	Border	delays,	R&D	disruption	and	regulatory
divergence	pose	hazards	to	this	important	industry,	writes	Jianwei	Xu.
Despite	numerous	debates	about	the	impact	of	Brexit,	the	pharmaceutical	industry	seems	to	be
less	eye-catching	than	other	sectors	like	the	manufacturing	supply	chain	and	financial	services.
However,	pharmaceuticals	are	one	of	the	EU’s	most	important	and	fastest-growing	industries,	and
they	benefit	greatly	from	EU	integration.
The	pharmaceutical	sector	in	the	EU	has	increased	from	€125	billion	to	€225	billion	over	the	past	15	years.
Employment	in	the	sector	also	grew	dramatically	from	535.000	to	725.000.	Pharmaceuticals	have	also	become
very	advantageous	for	the	EU.	Exports	of	pharmacy	products	have	more	than	tripled	over	the	past	15	years,	with
most	of	these	gains	obtained	from	extra-EU	transactions.	This	is	also	the	third	largest	industry	in	the	UK,
contributing	10	per	cent	of	the	country’s	GDP,	with	an	employment	of	73.000	people	and	a	trade	surplus	of	€3.3
billion.
Table	1.	The	rapid	growth	of	the	European	pharmaceutical	industry
Source:	“The	pharmaceutical	industry	in	figures”,	2016,	European	federation	of	pharmaceutical	industries	and	associations.
Figure	1.	Trade	balance	for	the	pharmaceutical	industry	(unit:	€million)
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Source:	data	collected	from	tradesmap.org	for	HS30	“Pharmaceutical	products”
The	rapid	advance	of	the	pharmaceutical	sector	over	the	past	decade	can	be	closely	associated	with	the
integration	of	the	EU	trade	chain.	In	2016,	around	67	per	cent	of	the	EU’s	exports	of	its	products	were	intra-EU
exports;	52	per	cent	of	the	EU’s	imports	of	its	products	were	intra-EU	imports.	According	to	EFPIA	figures,	among
the	EU	member	states	the	UK	is	undoubtedly	a	key	player,	constituting	10	per	cent	of	the	EU’s	total	production
and	employment.	Moreover,	the	UK	runs	a	trade	deficit	of	€114	billion	against	the	other	EU27	countries,	implying
that	it	is	a	major	destination	for	EU	pharmaceutical	products.
Figure	2.	Development	of	the	pharmaceutical	sector	across	EU	member	states
Source:	“The	pharmaceutical	industry	in	figures”,	2016,	European	Federation	of	Pharmaceutical	Industries	and	Associations.
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Non-tariff	barriers	such	as	the	possible	establishment	of	physical	border	could	have	negative	effects	on
pharmaceutical	trade
Fortunately,	the	EU	has	long	adopted	zero	most-favored-nation	tariffs	even	for	international	extra-EU	transactions
for	pharmaceutical	products.	So	the	worst	scenario,	even	in	a	hard	Brexit	where	the	EU	and	UK	treat	each	other
in	the	WTO	multilateral	framework	manner,	would	not	add	a	specific	tariff	burden	on	pharmaceutical	trade.
However,	tariffs	are	not	the	only	barrier	to	trade.	There	is	also	a	possibility	that	other	types	of	non-tariff	barriers
could	be	created	to	hamper	pharmaceutical	trade.	In	particular,	with	the	strengthening	of	immigration	control,
border	checks	might	be	resumed	which	could	create	delays	in	transferring	pharmaceutical	products	to/from	the
UK.	Longer	lead	times	and	increased	paperwork	caused	by	these	customs	bottlenecks	could	affect	service	levels
and	margins	–	especially	for	pharmaceutical	products,	which	have	a	short	shelf	life.	Evidence	has	shown	that,	for
time-sensitive	industries,	every	1	hour	of	customs	delay	adds	0.8	percentage	points	to	the	ad	valorem	trade-cost
rate	and	leads	to	5	per	cent	less	trade.	This	means	that	perishable	pharmaceutical	products	are	likely	to	cost
more	for	UK	residents,	especially	in	the	case	of	emergency.
The	establishment	of	a	physical	border	also	matters	particularly	for	Ireland.	Ireland	is	the	only	country	that	shares
a	land	border	with	the	UK.	Although	it	is	hard	to	say	what	will	eventually	happen	in	the	event	of	Brexit	until	the
final	post-Brexit	model	is	determined,	the	risk	has	been	mounting	since	Theresa	May’s	report	signaling	a	hard
Brexit.	Establishing	an	Irish-Irish	border	would	mean	that	Irish	pharmaceutical	products	need	to	go	across	the	UK
border	twice	before	entering	the	rest	of	the	EU.	One	solution	to	avoid	this	additional	processing	cost	is	to
construct	a	common	border	for	two	countries,	which	was	already	the	case	for	passengers	from	16	countries	such
as	China	and	India	to	enter	the	region.	But	that	undoubtedly	means	additional	costs	for	Irish	pharmaceutical
consumers.
Disruption	of	research	and	development	(R&D)	activities
One	of	the	key	characteristics	of	the	pharmaceutical	industry	is	its	high	intensity	in	research	and	development.
Figure	3	shows	that	the	pharmaceutical	and	biotechnology	sector	accounts	for	the	highest	R&D	intensity	in	the
EU,	even	higher	than	the	software	and	computer	services	sector.	Eurostat	data	also	indicates	that	the
pharmaceutical	industry	has	the	highest	added-value	per	person	employed.
Figure	3.	Comparisons	of	R&D	intensity	across	sectors
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Source:	The	2015	EU	Industrial	R&D	Investment	Scoreboard,	European	Commission,	JRC/DG	RTD
Within	the	pharmaceutical	industry,	the	UK	has	long	been	a	centre	for	research	and	development	(R&D)
activities.	In	2015,	it	contributed	approximately	20	per	cent	of	the	EU’s	total	R&D,	only	slightly	lower	than
Germany	and	France.	As	Maria	Demertzis	and	Enrico	Nano	highlight,	these	research	and	development	activities
rely	on	two	key	factors:	skilled	labour	supply	and	research	funding.	Both	factors	could	be	at	risk	in	the	post-Brexit
era.	For	the	former,	the	UK	has	attracted	a	large	number	of	skilled	workers	from	abroad,	most	of	which	are	EU
citizens.	For	the	latter,	the	UK	gains	more	research	funding	in	the	current	system	than	any	other	country.
Therefore,	Brexit	could	undoubtedly	have	a	negative	impact	for	both	factors	in	the	pharmacy	industry.
Figure	4:	R&D	contributions	in	pharmacy	industry
LSE Brexit: The pharmaceutical industry is at risk from Brexit Page 4 of 6
	
	
Date originally posted: 2017-07-17
Permalink: http://blogs.lse.ac.uk/brexit/2017/07/17/the-pharmaceutical-industry-is-at-risk-from-brexit/
Blog homepage: http://blogs.lse.ac.uk/brexit/
Source:	“The	Pharmaceutical	Industry	in	Figures”,	2016,	European	Federation	of	Pharmaceutical	Industries	and	Associations
In	addition,	research	and	development	in	the	pharmaceutical	industry	rely	on	protections	on	trademarks	and
associated	rights,	which	are	currently	covered	by	EU	laws.	The	future	of	these	activities	after	Brexit	depends	on
the	intellectual	protection	coordination	arrangement	between	the	EU	and	UK.	The	further	the	arrangement	goes
away	from	the	current	system,	the	more	challenging	the	future	will	be.
Regulatory	segmentation
The	unification	of	the	regulatory	framework	on	product	standards	has	eased	entry	barriers	for	pharmaceutical
companies	in	the	EU.	For	example,	the	current	product	standard	in	the	European	Economic	Area	(EEA)	is
authorised	by	the	London-based	European	Medicines	Agency	(EMA),	meaning	that	all	drugs	approved	by	EMA
are	automatically	granted	access	to	the	UK’s	market.	If	the	UK’s	post-Brexit	relationship	with	the	EU	does	not
include	a	shared	regulatory	framework,	access	to	both	markets	would	be	subject	to	additional	process.	Any
disruption	is	likely	to	lead	to	a	geographic	reallocation	of	the	pharmaceutical	industry.	This	can	be	detrimental	for
the	UK	but	could	be	an	opportunity	for	substitutive	countries	taking	on	this	business.
The	EMA	being	in	London	is	also	the	reason	why	a	number	of	influential	pharmacy	companies	choose	to	locate
their	European	headquarters	in	the	UK.	Ironically,	even	the	European	Medicine	Agency	(EMA)	may	find	itself	in
an	awkward	situation	after	Brexit,	because	it	is	currently	located	in	Canary	Wharf,	London.	It	is	highly	unlikely	that
the	UK	can	keep	the	medical	authority,	and	the	long-term	benefits	to	the	UK	from	proximity	to	the	EMA	will	also
be	lost.
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Conclusions
The	impact	of	Brexit	on	the	European	and	British	pharmaceutical	industry	will	go	far	beyond	the	simple	trade
analysis	based	on	tariffs	but	to	more	non-tariff	aspects.	The	establishment	of	a	physical	border	will	cause	delay	in
transportation	not	only	for	the	UK	but	also	Ireland.	This	may	increase	the	cost	of	pharmaceutical	products
especially	those	with	short	expiration	date.
Moreover,	a	UK	outside	of	the	EU	might	find	it	difficult	to	attract	skilled	experts	for	the	industry,	lose	research
funding	supported	by	the	EU,	and	face	barriers	accessing	the	EU27	market.	For	the	rest	of	the	EU,	Brexit	could
also	cause	similar	additional	costs	on	the	whole,	but	given	its	larger	economic	size	than	the	UK,	the	loss	would
also	be	smaller.	For	some	EU	countries,	if	they	can	seize	the	opportunity	to	take	on	UK	business,	or	become	the
new	location	for	the	EMA,	there	is	a	chance	to	benefit	despite	the	general	loss	in	the	EU.
Nonetheless,	the	best	strategy	to	reserve	benefits	for	both	the	EU	and	UK	is	still	to	maintain	the	existing
relationship	between	the	two	parties	on	all	the	related	aspects.	But	this	seems	to	be	an	increasingly	challenging
task	in	the	likely	scenario	of	a	hard	Brexit.
This	blog	post	was	originally	published	by	Bruegel	and	LSE	Business	Review.	The	post	gives	the	views	of	its
author,	not	the	position	of	LSE	Brexit	or	the	London	School	of	Economics.	Featured	image	credit:	Lab,	by
jdn2001cn0,	under	a	CC0	licence.
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works	as	an	affiliate	fellow	at	China	Academy	of	Social	Science	and	a	youth	member	of	the	China	Finance	Forum
40.
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